SCHEMBL5740325

SCHEMBL5740325

CCC1CCc2c(sc3cc(-c4cc(C)cs4)ccc3c2=O)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
GAA P10253 1/20 0.35
ABL1 P00519 1/20 0.34
CHEK1 O14757 1/20 0.33
FABP4 P15090 7/20 0.33
FABP5 Q01469 7/20 0.33
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
THRB P10828 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
XBP1 P17861 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TNIK Q9UKE5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5739488 0.86 MAPT (0.38) ALDH1A1MAPTHPGDGAATHRB
SCHEMBL5740727 0.84 KIF11 (0.40) ALDH1A1MAPTHPGDGAAHDAC3
SCHEMBL5739368 0.84 MAPT (0.41) ALDH1A1MAPTHPGDGAATHRB
SCHEMBL5740793 0.82 KDM4E (0.38) ALDH1A1MAPTHPGDGAAABL1
SCHEMBL5738978 0.82 TNIK (0.41) ALDH1A1MAPTHPGDGAATHRB
SCHEMBL5741517 0.81 ALDH1A1 (0.34) ALDH1A1MAPTHPGDGAATHRB
SCHEMBL5741212 0.81 TNIK (0.37) ALDH1A1MAPTHPGDGAATHRB
SCHEMBL5741298 0.81 BRD4 (0.39) ALDH1A1MAPTHPGDGAATHRB
SCHEMBL5740604 0.81 PRF1 (0.36) ALDH1A1MAPTHPGDGAATHRB
SCHEMBL5742394 0.80 PGR (0.38) ALDH1A1MAPTHPGDGAATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406891-B1 THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES BAYER HEALTHCARE AG (DE) 2006-03-22 EP disclosed
US-20050009820-A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases BAYER HEALTHCARE AG (DE) 2005-01-13 US disclosed
EP-1406891-A1 THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES Bayer HealthCare AG (DE) 2004-04-14 EP disclosed
WO-2003053955-A1 THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES BAYER HEALTHCARE AG (DE) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009820-A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases HTT, HMOX1, SNCA ALDH1A1 1088/4885MAPT 29/4885HPGD 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.